Lisata Depreciation vs Free Cash Flow Analysis

LSTA Stock

USD 2.62 0.04 1.55%

Lisata Therapeutics financial indicator trend analysis is infinitely more than just investigating Lisata Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lisata Therapeutics is a good investment. Please check the relationship between Lisata Therapeutics Depreciation and its Free Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.

Depreciation vs Free Cash Flow

Depreciation vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lisata Therapeutics Depreciation account and Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Lisata Therapeutics' Depreciation and Free Cash Flow is -0.69. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Lisata Therapeutics, assuming nothing else is changed. The correlation between historical values of Lisata Therapeutics' Depreciation and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Lisata Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Depreciation i.e., Lisata Therapeutics' Depreciation and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.69

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Depreciation

Depreciation indicates how much of Lisata Therapeutics value has been used up. For tax purposes Lisata Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Lisata Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Lisata Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lisata Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.The current year's Enterprise Value is expected to grow to about 36.1 M, whereas Selling General Administrative is forecasted to decline to about 6.7 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	29.1M	57.6M	25.7M	19.8M
Cost Of Revenue	55K	57.6M	189K	179.6K

Total Operating Expenses Cost Of Revenue

Lisata Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Intangible Assets	Cash	Cash And Short Term Investments	Good Will	Short Term Investments	Current Deferred Revenue
Total Assets		0.35	0.68	0.68	0.7	0.46	-0.02	0.12	0.5	0.81	0.12	-0.11	0.72	0.37	-0.02	0.75	0.38	0.27	0.19	0.65	0.63	0.19	0.11	0.63	0.01	0.1
Short Long Term Debt Total	0.35		0.09	0.52	-0.13	0.83	0.45	0.22	0.81	0.56	0.79	-0.38	0.7	0.71	-0.23	0.68	-0.32	0.7	0.17	0.01	0.65	-0.02	-0.39	0.55	-0.22	0.66
Other Current Liab	0.68	0.09		0.86	0.21	0.31	0.29	0.32	0.07	0.73	-0.11	-0.2	0.52	0.14	-0.27	0.68	-0.01	0.43	0.28	0.97	0.19	-0.28	-0.32	0.13	-0.28	-0.13
Total Current Liabilities	0.68	0.52	0.86		0.04	0.71	0.43	0.3	0.5	0.84	0.33	-0.31	0.76	0.46	-0.28	0.89	-0.19	0.76	0.3	0.79	0.4	-0.23	-0.48	0.34	-0.33	0.26
Total Stockholder Equity	0.7	-0.13	0.21	0.04		-0.14	-0.55	-0.3	0.12	0.2	-0.27	0.36	0.08	0.0	0.43	0.07	0.87	-0.32	-0.08	0.22	0.23	0.55	0.74	0.39	0.47	-0.11
Property Plant And Equipment Net	0.46	0.83	0.31	0.71	-0.14		0.33	0.34	0.83	0.71	0.72	-0.48	0.81	0.59	-0.35	0.82	-0.37	0.84	0.3	0.23	0.6	0.03	-0.5	0.48	-0.34	0.52
Net Debt	-0.02	0.45	0.29	0.43	-0.55	0.33		0.48	0.09	0.41	0.35	-0.41	0.41	0.25	-0.54	0.44	-0.69	0.58	0.47	0.33	0.27	-0.9	-0.75	0.08	-0.38	0.11
Retained Earnings	0.12	0.22	0.32	0.3	-0.3	0.34	0.48		-0.07	0.5	0.09	-0.66	0.4	-0.14	-0.99	0.39	-0.62	0.34	0.74	0.39	0.37	-0.44	-0.69	0.02	-0.66	-0.48
Accounts Payable	0.5	0.81	0.07	0.5	0.12	0.83	0.09	-0.07		0.55	0.81	-0.06	0.74	0.82	0.08	0.69	-0.03	0.55	-0.04	-0.02	0.67	0.3	-0.12	0.69	-0.09	0.69
Non Current Assets Total	0.81	0.56	0.73	0.84	0.2	0.71	0.41	0.5	0.55		0.36	-0.41	0.92	0.42	-0.45	0.95	-0.22	0.58	0.44	0.73	0.78	-0.19	-0.48	0.66	-0.49	0.07
Net Receivables	0.12	0.79	-0.11	0.33	-0.27	0.72	0.35	0.09	0.81	0.36		-0.1	0.6	0.74	-0.1	0.53	-0.32	0.49	-0.07	-0.16	0.5	0.0	-0.34	0.48	-0.21	0.6
Common Stock Shares Outstanding	-0.11	-0.38	-0.2	-0.31	0.36	-0.48	-0.41	-0.66	-0.06	-0.41	-0.1		-0.43	0.17	0.72	-0.43	0.55	-0.45	-0.4	-0.19	-0.33	0.3	0.58	-0.02	0.4	-0.06
Non Current Liabilities Total	0.72	0.7	0.52	0.76	0.08	0.81	0.41	0.4	0.74	0.92	0.6	-0.43		0.6	-0.37	0.97	-0.25	0.57	0.23	0.48	0.85	-0.12	-0.46	0.73	-0.42	0.33
Other Current Assets	0.37	0.71	0.14	0.46	0.0	0.59	0.25	-0.14	0.82	0.42	0.74	0.17	0.6		0.12	0.58	-0.04	0.44	-0.18	0.05	0.47	0.06	-0.15	0.47	-0.02	0.66
Other Stockholder Equity	-0.02	-0.23	-0.27	-0.28	0.43	-0.35	-0.54	-0.99	0.08	-0.45	-0.1	0.72	-0.37	0.12		-0.37	0.71	-0.38	-0.71	-0.34	-0.31	0.5	0.76	0.06	0.68	0.41
Total Liab	0.75	0.68	0.68	0.89	0.07	0.82	0.44	0.39	0.69	0.95	0.53	-0.43	0.97	0.58	-0.37		-0.24	0.68	0.28	0.62	0.73	-0.17	-0.49	0.62	-0.41	0.32
Total Current Assets	0.38	-0.32	-0.01	-0.19	0.87	-0.37	-0.69	-0.62	-0.03	-0.22	-0.32	0.55	-0.25	-0.04	0.71	-0.24		-0.48	-0.4	-0.05	-0.17	0.62	0.95	0.06	0.77	0.04
Short Term Debt	0.27	0.7	0.43	0.76	-0.32	0.84	0.58	0.34	0.55	0.58	0.49	-0.45	0.57	0.44	-0.38	0.68	-0.48		0.51	0.36	0.28	-0.32	-0.62	0.15	-0.26	0.44
Common Stock	0.19	0.17	0.28	0.3	-0.08	0.3	0.47	0.74	-0.04	0.44	-0.07	-0.4	0.23	-0.18	-0.71	0.28	-0.4	0.51		0.39	0.26	-0.46	-0.48	0.02	-0.34	-0.42
Non Currrent Assets Other	0.65	0.01	0.97	0.79	0.22	0.23	0.33	0.39	-0.02	0.73	-0.16	-0.19	0.48	0.05	-0.34	0.62	-0.05	0.36	0.39		0.2	-0.37	-0.35	0.12	-0.33	-0.29
Intangible Assets	0.63	0.65	0.19	0.4	0.23	0.6	0.27	0.37	0.67	0.78	0.5	-0.33	0.85	0.47	-0.31	0.73	-0.17	0.28	0.26	0.2		0.02	-0.28	0.91	-0.42	0.17
Cash	0.19	-0.02	-0.28	-0.23	0.55	0.03	-0.9	-0.44	0.3	-0.19	0.0	0.3	-0.12	0.06	0.5	-0.17	0.62	-0.32	-0.46	-0.37	0.02		0.66	0.19	0.31	0.19
Cash And Short Term Investments	0.11	-0.39	-0.32	-0.48	0.74	-0.5	-0.75	-0.69	-0.12	-0.48	-0.34	0.58	-0.46	-0.15	0.76	-0.49	0.95	-0.62	-0.48	-0.35	-0.28	0.66		-0.04	0.82	0.05
Good Will	0.63	0.55	0.13	0.34	0.39	0.48	0.08	0.02	0.69	0.66	0.48	-0.02	0.73	0.47	0.06	0.62	0.06	0.15	0.02	0.12	0.91	0.19	-0.04		-0.26	0.27
Short Term Investments	0.01	-0.22	-0.28	-0.33	0.47	-0.34	-0.38	-0.66	-0.09	-0.49	-0.21	0.4	-0.42	-0.02	0.68	-0.41	0.77	-0.26	-0.34	-0.33	-0.42	0.31	0.82	-0.26		0.31
Current Deferred Revenue	0.1	0.66	-0.13	0.26	-0.11	0.52	0.11	-0.48	0.69	0.07	0.6	-0.06	0.33	0.66	0.41	0.32	0.04	0.44	-0.42	-0.29	0.17	0.19	0.05	0.27	0.31

Click cells to compare fundamentals

Lisata Therapeutics Account Relationship Matchups

Lisata Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.2M	36.0M	97.0M	73.0M	54.7M	43.4M
Other Current Liab	1.6M	2.1M	2.4M	3.5M	4.0M	3.4M
Total Current Liabilities	6.0M	3.5M	4.5M	6.4M	6.6M	8.5M
Total Stockholder Equity	20.8M	32.5M	92.3M	66.6M	48.1M	50.6M
Property Plant And Equipment Net	100K	57K	62K	296K	483K	458.9K
Net Debt	(13.7M)	(15.9M)	(23.9M)	(31.7M)	(22.3M)	(21.2M)
Retained Earnings	(417.4M)	(425.6M)	(453.0M)	(507.2M)	(528.1M)	(501.7M)
Accounts Payable	1.5M	1.0M	1.9M	2.7M	2.4M	2.4M
Non Current Assets Total	1.2M	671K	826K	1.2M	770K	731.5K
Common Stock Shares Outstanding	688.3K	1.0M	3.7M	5.2M	8.1M	8.5M
Liabilities And Stockholders Equity	27.2M	36.0M	97.0M	73.0M	54.7M	43.4M
Non Current Liabilities Total	624K	254K	485K	327K	210K	199.5K
Other Current Assets	815K	758K	1.2M	2.7M	3.4M	1.7M
Other Stockholder Equity	438.2M	458.0M	545.3M	573.8M	576.3M	605.1M
Total Liab	6.6M	3.8M	5.0M	6.7M	6.8M	6.5M
Total Current Assets	26.0M	35.3M	96.2M	71.9M	53.9M	56.6M
Accumulated Other Comprehensive Income	2K	(13K)	(70K)	(29K)	(42K)	(44.1K)
Common Stock	11K	19K	60K	8K	7.2K	6.8K
Non Currrent Assets Other	1.1M	614K	764K	528K	24K	22.8K
Cash	14.0M	16.5M	24.6M	32.2M	22.6M	23.7M
Cash And Short Term Investments	25.2M	34.6M	95.0M	69.2M	50.5M	53.1M
Short Term Investments	11.1M	18.1M	70.3M	37.1M	27.9M	18.7M
Other Assets	309K	0.0	40K	1.2M	1.4M	1.5M
Net Invested Capital	20.8M	32.5M	92.3M	66.6M	48.1M	54.6M
Capital Stock	11K	19K	60K	8K	9.2K	8.7K
Net Working Capital	20.0M	31.8M	91.7M	65.5M	47.3M	54.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:

How To Invest In Lisata

Details

Is Lisata Stock a good investment?

Details

What is Lisata Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.51)

Return On Assets

(0.29)

Return On Equity

(0.44)

The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lisata Depreciation vs Free Cash Flow Analysis

Depreciation vs Free Cash Flow

Depreciation vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Depreciation

Free Cash Flow

Lisata Therapeutics fundamental ratios Correlations

Lisata Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lisata Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 0.97	Other Current Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Total Liab	+ 0.95	Non Current Assets Total
Cash And Short Term Investments	+ 0.95	Total Current Assets
Non Current Liabilities Total	+ 0.92	Non Current Assets Total
Good Will	+ 0.91	Intangible Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.9	Net Debt
Cash And Short Term Investments	- 0.75	Net Debt
Common Stock	- 0.71	Other Stockholder Equity
Cash And Short Term Investments	- 0.69	Retained Earnings
Total Current Assets	- 0.69	Net Debt